Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$17.75 - $41.6 $798,856 - $1.87 Million
45,006 Added 15.17%
341,701 $13.5 Million
Q4 2023

Feb 13, 2024

BUY
$8.54 - $20.22 $224,354 - $531,199
26,271 Added 9.71%
296,695 $5.66 Million
Q3 2023

Nov 13, 2023

BUY
$10.13 - $13.98 $130,677 - $180,342
12,900 Added 5.01%
270,424 $3.1 Million
Q2 2023

Aug 11, 2023

BUY
$6.84 - $11.91 $434,593 - $756,725
63,537 Added 32.75%
257,524 $2.65 Million
Q1 2023

May 15, 2023

BUY
$7.0 - $8.75 $16,905 - $21,131
2,415 Added 1.26%
193,987 $1.5 Million
Q4 2022

Feb 13, 2023

BUY
$5.45 - $7.35 $365,662 - $493,140
67,094 Added 53.9%
191,572 $1.41 Million
Q3 2022

Nov 14, 2022

SELL
$6.89 - $9.39 $8,929 - $12,169
-1,296 Reduced 1.03%
124,478 $896,000
Q2 2022

Aug 12, 2022

BUY
$6.71 - $9.52 $161,482 - $229,108
24,066 Added 23.66%
125,774 $1.07 Million
Q1 2022

May 13, 2022

SELL
$6.41 - $13.89 $24,915 - $53,990
-3,887 Reduced 3.68%
101,708 $912,000
Q4 2021

Feb 08, 2022

SELL
$10.41 - $13.95 $17,061 - $22,864
-1,639 Reduced 1.53%
105,595 $1.46 Million
Q3 2021

Nov 15, 2021

SELL
$8.19 - $11.31 $51,965 - $71,761
-6,345 Reduced 5.59%
107,234 $1.14 Million
Q2 2021

Aug 13, 2021

BUY
$8.81 - $15.03 $825,197 - $1.41 Million
93,666 Added 470.38%
113,579 $1.02 Million
Q1 2021

May 12, 2021

BUY
$10.02 - $13.92 $1,122 - $1,559
112 Added 0.57%
19,913 $211,000
Q4 2020

Feb 11, 2021

BUY
$7.42 - $15.96 $37,604 - $80,885
5,068 Added 34.4%
19,801 $249,000
Q3 2020

Nov 16, 2020

BUY
$7.15 - $11.5 $105,340 - $169,429
14,733 New
14,733 $130,000
Q2 2020

Aug 14, 2020

SELL
$2.77 - $12.1 $28,220 - $123,274
-10,188 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$2.45 - $3.87 $176 - $278
-72 Reduced 0.7%
10,188 $39,000
Q3 2019

Nov 13, 2019

SELL
$3.5 - $5.0 $350 - $500
-100 Reduced 0.97%
10,260 $41,000
Q1 2019

May 13, 2019

BUY
$4.09 - $7.19 $42,372 - $74,488
10,360 New
10,360 $71,000

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.